Mesoblast (NASDAQ:MESO) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.01 by 500 percent. This is a 50 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $120.250 million which beat the analyst consensus estimate of $66.000 million by 82.20 percent. This is a 599.21 percent increase over sales of $17.198 million the same period last year.